How does AAPG's PS Ratio compare to its peers?

AAPG is good value based on its Price-To-Sales Ratio (12.8x) compared to the peer average (19.6x).

How does AAPG's PS Ratio compare vs other companies in the US Biotechs Industry?

AAPG is expensive based on its Price-To-Sales Ratio (12.8x) compared to the US Biotechs industry average (11.1x).

What is AAPG's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

Insufficient data to calculate AAPG's Price-To-Sales Fair Ratio for valuation analysis.

What is the Fair Price of AAPG when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

AAPG ($18.8) is trading above our estimate of [[fair value]] ($3.29)

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Insufficient data to show price forecast.

Ascentage Pharma Group International (Nasdaq:AAPG) - Stock Price, News & Analysis

AAPG Stock Overview

A clinical-stage biotechnology company, develops therapies for cancers, chronic hepatitis B virus (HBV), and age-related diseases in Mainland China. More details

AAPG fundamental analysis
Snowflake Score
Valuation	1/6
Future Growth	3/6
Past Performance	0/6
Financial Health	4/6
Dividends	0/6

Rewards

Revenue is forecast to grow 23.29% per year

Earnings have grown 10.4% per year over the past 5 years

Risk Analysis

Shares are highly illiquid

Shareholders have been diluted in the past year

Currently unprofitable and not forecast to become profitable over the next 3 years

My Notes

Capture your thoughts, links and company narrative

Ascentage Pharma Group International Competitors

Ardelyx

NasdaqGM:ARDX

US$1.3b

Beam Therapeutics

NasdaqGS:BEAM

US$2.2b

Agios Pharmaceuticals

NasdaqGS:AGIO

US$2.0b

Protagonist Therapeutics

NasdaqGM:PTGX

US$2.3b

Price History & Performance

Summary of share price highs, lows and changes for Ascentage Pharma Group International
Historical stock prices
Current Share Price	HK$18.80
52 Week High	HK$18.95
52 Week Low	HK$16.50
Beta	1
1 Month Change	n/a
3 Month Change	n/a
1 Year Change	n/a
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	8.17%

Recent News & Updates

No updates

Recent updates

No updates

Shareholder Returns

	AAPG	US Biotechs	US Market
7D	6.8%	1.3%	0.2%
1Y	n/a	0.9%	22.0%

Return vs Industry: Insufficient data to determine how AAPG performed against the US Biotechs industry.

Return vs Market: Insufficient data to determine how AAPG performed against the US Market.

Price Volatility

Is AAPG's price volatile compared to industry and market?
AAPG volatility
AAPG Average Weekly Movement	n/a
Biotechs Industry Average Movement	11.4%
Market Average Movement	6.1%
10% most volatile stocks in US Market	18.6%
10% least volatile stocks in US Market	3.1%

Stable Share Price: AAPG's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: Insufficient data to determine AAPG's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
2009	574	Dajun Yang	www.ascentage.cn

Ascentage Pharma Group International, a clinical-stage biotechnology company, develops therapies for cancers, chronic hepatitis B virus (HBV), and age-related diseases in Mainland China. The company’s primary product candidate is HQP1351, a BCR-ABL inhibitor targeting BCR-ABL1 mutants, including those with the T315I mutation. It also develops APG-2575, an oral administered Bcl-2 selective inhibitor for hematologic malignancies and solid tumors; APG-115, an oral small molecule inhibitor of the MDM2-p53 protein-protein interactions to treat solid tumors and hematological malignancies; and APG-1252, a small molecule drug to restore apoptosis through dual inhibition of the Bcl-2 and Bcl-xL proteins for the treatment of small-cell lung cancer, non-small cell lung cancer, neuroendocrine tumor, and non-Hodgkin’s lymphoma.

Ascentage Pharma Group International Fundamentals Summary

How do Ascentage Pharma Group International's earnings and revenue compare to its market cap?
AAPG fundamental statistics
Market cap	US$1.59b
Earnings (TTM)	-US$49.43m
Revenue (TTM)	US$123.90m

12.8x

P/S Ratio

-32.2x

P/E Ratio

Is AAPG overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
AAPG income statement (TTM)
Revenue	CN¥903.03m
Cost of Revenue	CN¥27.45m
Gross Profit	CN¥875.58m
Other Expenses	CN¥1.24b
Earnings	-CN¥360.28m

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	-1.06
Gross Margin	96.96%
Net Profit Margin	-39.90%
Debt/Equity Ratio	216.3%

How did AAPG perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/02/06 08:28
End of Day Share Price	2025/02/06 00:00
Earnings	2024/06/30
Annual Earnings	2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Ascentage Pharma Group International is covered by 13 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Yang Huang	BofA Global Research
Jin Zhang	China International Capital Corporation Limited
Wangbin Zhou	China International Capital Corporation Limited